» Articles » PMID: 27381839

Relapse of Pemphigus Vulgaris After Topical Application of Ingenol Mebutate

Overview
Specialty Dermatology
Date 2016 Jul 7
PMID 27381839
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Ingenol mebutate is a recently approved topical agent for the treatment of actinic keratosis. Its most common adverse effects are transient local skin reactions. We report a 63-year-old white man who presented with a red-brownish crusted plaque involving the dorsum of his nose and an eroded area on his lower lip, which appeared soon after topical application of ingenol mebutate gel. Clinical, histological and immunopathological features were consistent with a diagnosis of pemphigus vulgaris (PV). To our knowledge, this is the first report of relapse of PV after topical application of ingenol mebutate gel. The temporal relationship between the application of the drug and the outbreak of PV supports the involvement of this agent in triggering the disease. It is plausible that ingenol mebutate may have induced the disease by its action on the production of proinflammatory cytokines.

Citing Articles

Pemphigus: trigger and predisposing factors.

Moro F, Sinagra J, Salemme A, Fania L, Mariotti F, Pira A Front Med (Lausanne). 2024; 10:1326359.

PMID: 38213911 PMC: 10783816. DOI: 10.3389/fmed.2023.1326359.


The multifactorial complexities of autoimmune development in Pemphigus vulgaris: Critical evaluation of the role of environmental and lifestyle "exposome" factors.

Adebiyi O, Galloway D, Augustin M, Sinha A Front Immunol. 2023; 13:1058759.

PMID: 36703956 PMC: 9871583. DOI: 10.3389/fimmu.2022.1058759.


A Case of New-Onset Pemphigus Erythematosus after Topical Application of Ingenol Mebutate.

Yang H, Lee W, Won C, Chang S, Lee M, Choi J Indian J Dermatol. 2022; 66(5):563-565.

PMID: 35068520 PMC: 8751704. DOI: 10.4103/ijd.ijd_820_20.